Onvansertib Combo Shows Significant Efficacy in KRAS+ Colorectal Cancer
For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.
Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Bridging Racial and Ethnic Minority Disparities in Pancreatic Cyst Surveillance
A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.
Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
